{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:19:48Z","timestamp":1791443988194,"version":"4.3.3"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejca.2026.117008","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T14:46:43Z","timestamp":1787410003000},"page":"117008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Hypomethylating agents with venetoclax for newly diagnosed acute myeloid leukemia in patients 65 and older in The Netherlands \u2013 A nationwide study of drug usage and treatment outcomes"],"prefix":"10.1016","volume":"246","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5514-471X","authenticated-orcid":false,"given":"Benno","family":"Diekmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolien M.","family":"Woolthuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1326-4446","authenticated-orcid":false,"given":"Maarten F.","family":"Corsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"de Leeuw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roel B.","family":"Fiets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Segarceanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleur M.","family":"van der Valk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim T.","family":"de Waal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Cruijsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7416-5794","authenticated-orcid":false,"given":"Eva","family":"de Jongh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjeerd","family":"Snijders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8504-1938","authenticated-orcid":false,"given":"Danielle","family":"van Lammeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4133-769X","authenticated-orcid":false,"given":"Aart","family":"Beeker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra H.E.","family":"Herbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0771-5231","authenticated-orcid":false,"given":"Lidwine","family":"Tick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Franken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1492-7937","authenticated-orcid":false,"given":"Nic J.G.M.","family":"Veeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric N.","family":"van Roon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8032-2592","authenticated-orcid":false,"given":"Mels","family":"Hoogendoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejca.2026.117008_bib1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2026.117008_bib2","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00277-024-05891-w","article-title":"A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold?","volume":"104","author":"Solana-Altabella","year":"2025","journal-title":"Ann Hematol"},{"issue":"18","key":"10.1016\/j.ejca.2026.117008_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15184618","article-title":"Venetoclax with hypomethylating agents in newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis of survival data from real-world studies","volume":"15","author":"Ucciero","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ejca.2026.117008_bib4","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/10428194.2014.910657","article-title":"Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies","volume":"56","author":"Bogenberger","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.ejca.2026.117008_bib5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments","volume":"39","author":"Agarwal","year":"2017","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.ejca.2026.117008_bib6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00280-020-04179-w","article-title":"Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach","volume":"87","author":"Bhatnagar","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2026.117008_bib7","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024027506","article-title":"The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy","author":"Daver","year":"2025","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ejca.2026.117008_bib8","doi-asserted-by":"crossref","first-page":"e830","DOI":"10.1016\/S2352-3026(24)00241-2","article-title":"Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial","volume":"11","author":"Russo","year":"2024","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.ejca.2026.117008_bib9","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.ejca.2026.117008_bib10","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/S2352-3026(23)00273-9","article-title":"10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial","volume":"10","author":"Lubbert","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ejca.2026.117008_bib11","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2025.288178","article-title":"Venetoclax plus hypomethylating agents as a bridge to transplant or donor lymphocyte infusion in relapsed\/refractory acute myeloid leukemia","author":"Verdeyen","year":"2025","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.ejca.2026.117008_bib12","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.26190","article-title":"Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice","volume":"96","author":"Apel","year":"2021","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.ejca.2026.117008_bib13","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41408-025-01269-x","article-title":"Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients","volume":"15","author":"Willekens","year":"2025","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.ejca.2026.117008_bib14","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00277-023-05102-y","article-title":"Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia","volume":"102","author":"Aiba","year":"2023","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.ejca.2026.117008_bib15","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"issue":"31","key":"10.1016\/j.ejca.2026.117008_bib16","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study","volume":"33","author":"Granfeldt Ostgard","year":"2015","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ejca.2026.117008_bib17","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"Dohner","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejca.2026.117008_bib18","article-title":"Regional disparities in the use of intensive chemotherapy for AML in the Netherlands: does it influence survival?","volume":"3","author":"Kaplan","year":"2024","journal-title":"BMJ Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2026.117008_bib19","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2016.71.2208","article-title":"Genomics of acute myeloid leukemia diagnosis and pathways","volume":"35","author":"Bullinger","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2026.117008_bib20","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ejca.2026.117008_bib21","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.ejca.2026.117008_bib22","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1182\/blood.2024026925","article-title":"Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML","volume":"144","author":"Lachowiez","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ejca.2026.117008_bib23","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejca.2026.117008_bib24","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/ajh.27613","article-title":"Prospective pharmacokinetic evaluation of venetoclax in AML supports re-evaluation of recommended dose adjustments with azole antifungals","volume":"100","author":"Kawedia","year":"2025","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.ejca.2026.117008_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2023.101631","article-title":"New treatment opportunities for older patients with acute myeloid leukemia and the increasing importance of frailty assessment \u2013 an oncogeriatric perspective","volume":"15","author":"Diekmann","year":"2024","journal-title":"J Geriatr Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2026.117008_bib26","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/ejh.14278","article-title":"Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy","volume":"113","author":"Acker","year":"2024","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.ejca.2026.117008_bib27","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41408-024-00996-x","article-title":"How comparable are patient outcomes in the \"real-world\" with populations studied in pivotal AML trials?","volume":"14","author":"Tiong","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ejca.2026.117008_bib28","article-title":"Treatment patterns and real-world outcomes of molecular subgroups in patients with AML receiving frontline venetoclax-based therapy","author":"Lachowiez","year":"2025","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"10.1016\/j.ejca.2026.117008_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13020584","article-title":"Real-life multicenter experience of venetoclax in combination with hypomethylating agents in previously untreated adult patients with acute myeloid leukemia in Greece","volume":"13","author":"Chatzilygeroudi","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejca.2026.117008_bib30","article-title":"The use of antifungal prophylaxis is associated with worse outcomes in patients with newly diagnosed AML treated with venetoclax\/HMA: a retrospective analysis of patients in the Flatiron health database","volume":"144","author":"Alexander","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ejca.2026.117008_bib31","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1111\/bjh.19670","article-title":"Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis","volume":"205","author":"Weinbergerova","year":"2024","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.ejca.2026.117008_bib32","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2293512","article-title":"Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia","volume":"29","author":"Cui","year":"2024","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.ejca.2026.117008_bib33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41408-025-01270-4","article-title":"Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days","volume":"15","author":"Gangat","year":"2025","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.ejca.2026.117008_bib34","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/ajh.27417","article-title":"Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment","volume":"99","author":"Garciaz","year":"2024","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.ejca.2026.117008_bib35","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.2024025464","article-title":"Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes","volume":"145","author":"Garcia","year":"2025","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ejca.2026.117008_bib36","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1182\/blood.2024027567","article-title":"Azacitidine and venetoclax for HR-MDS: election results pending","volume":"145","author":"Venugopal","year":"2025","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.ejca.2026.117008_bib37","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2026.117008_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100016","article-title":"Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia","volume":"1","author":"Madarang","year":"2024","journal-title":"Blood Neoplasia"},{"issue":"10","key":"10.1016\/j.ejca.2026.117008_bib39","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1007\/s00277-024-05923-5","article-title":"Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study","volume":"103","author":"Jimenez-Vicente","year":"2024","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.ejca.2026.117008_bib40","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.3324\/haematol.2024.286589","article-title":"Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia","volume":"110","author":"Jimenez-Vicente","year":"2025","journal-title":"Haematologica"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:10:41Z","timestamp":1789056641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926007896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":40,"alternative-id":["S0959804926007896"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117008","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypomethylating agents with venetoclax for newly diagnosed acute myeloid leukemia in patients 65 and older in The Netherlands \u2013 A nationwide study of drug usage and treatment outcomes","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"117008"}}